Naoto Tada Ueno, M.D., Ph.D., F.A.C.P.
Present Title & Affiliation
I have a strong background in translational breast cancer research in the areas of cancer biology and molecular therapeutics, with specific training and expertise in the key research areas of EGFR/ERK signaling and in vivo modeling. As a Ph.D. student at The UT Graduate School of Biomedical Sciences, I carried out preclinical research on the role of the HER2 pathway in chemosensitization of paclitaxel in breast cancer. In addition to my basic research background, I trained as a medical oncologist at MD Anderson and simultaneously learned how to conduct clinical research and perform data analysis related to breast cancer. I am now a practicing physician who has experience in conducting both targeted and gene therapy clinical trials.
Since becoming a faculty member at MD Anderson, I have expanded my research to include the EGFR/ERK pathway in both breast and ovarian cancer (HER2, JNK, TIG1, FOXO3, epigenetic,etc.). Over the past 10 years, I have successfully managed projects in breast cancer biology related to triple-negative breast cancer, inflammatory breast cancer, metastasis, cancer stem cells, and drug resistance of cancer cells. Currently I serve as an executive director of Morgan Welch Inflammatory Breast Cancer (MWIBC) Research Program and Clinic and Section of Translational Breast Cancer Research (TBCR). MD Anderson MWIBC is the world’s largest IBC specific resarch program that conducts IBC-specific clinical trials, understanding the aggressiveness of caners by studying cancer stem cells, and the impact of microenviroment (infllmationn and immunolgoical efect). For the section of TBCR, the program focuses on reducing the suffering of breast cancer patients through our unique, rapid drug development platforms via enhanced value of novel therapeutic approach and guiding to investigator-initiated clinical trials or standard of care.
Education & Training
|1999||The University of Texas Graduate School of Biomedical Sciences, Houston, TX, PHD, Cancer Biology|
|1989||Wakayama Medical College, Wakayama,, Japan, MD, Doctor of Medicine|
|7/1993-6/1996||Clinical Fellowship, Medical Oncology and Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX|
|7/1991-6/1993||Clinical Residency, Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA|
|7/1990-4/1991||Clinical Internship, Internal Medicine, Montefiore University Hospital - University of Pittsburgh, Pittsburgh, PA|
|4/1989-3/1990||Clinical Internship, Rotating Internship, United States Naval Hospital, Yokosuka, Kanagawa, Japan|
|1995||American Board of Internal Medicine - Medical Oncology, Recertification Date: 2015|
|1993||American Board of Internal Medicine - Internal Medicine, Recertification Date: 2014|
Institutional Committee Activities
Honors and Awards
|2013-2014||Regents Outstanding Teaching Award, The University of Texas System|
|2012-present||Waun Ki Hong Award for Excellence in Team Science, Division of Cancer Medicine Faculty Recognition and Awards Program|
|1.||Matsuda N, Wang X, Krishnamurthy S, Alvarez RH, Willey JS, Lim B, Parker CA, Gildy BV, Booser DJ, Murray JL, Arun BK, Brewster A, Reuben JM, Stauder M, Woodward W, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer. ASCO 2016 (#1087, Board #192), 6/2016.|
|1.||Ueno, NT, Champlin R. Autologous Transplantation. In: Medical oncology, A Comprehensive Review. PRR, 151-165, 1996.|
Last updated: 10/20/2016